EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSTUG00000046374
Gene Symbol: PIK3R5
3 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSTUG00000001761
Gene Symbol: PIK3R5
3 Cross references
194 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSSTUG00000000250
Gene Symbol: PLA2G7
3 Cross references
196 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSSTUG00000022538
Gene Symbol: LOC115178644
2 Cross references
174 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSSTUG00000021682
Gene Symbol: LOC115178659
2 Cross references
174 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSSTUG00000010101
Gene Symbol: LOC115171168
3 Cross references
226 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSSTUG00000024852
Gene Symbol: LOC115198616
3 Cross references
225 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSSTUG00000005597
Gene Symbol: GART
1 Cross references
240 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSSTUG00000048600
Gene Symbol: GART
3 Cross references
239 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSSTUG00000037975
Gene Symbol: PLAT
3 Cross references
199 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSSTUG00000047668
Gene Symbol: PLAT
3 Cross references
199 Possible Orthologues:

Plasminogen-Like

Ensembl ID : ENSSTUG00000008329
Gene Symbol: LOC115192977
3 Cross references
250 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).